Publications by authors named "Victoria Nartallo Penas"
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Hum Vaccin Immunother
December 2024
Article Synopsis
- Nirsevimab has been approved for universal RSV prevention in infants, with a study (NIRSE-GAL) launched in Galicia in September 2023 to assess its effectiveness against various RSV-related health issues.
- The study will monitor infants during the RSV season, focusing on different groups including newborns and those at high risk, and will track outcomes until significant events occur or the study concludes.
- Data analysis will utilize sophisticated models and will include safety monitoring of nirsevimab, with results communicated through scientific publications and conferences.
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Lancet Infect Dis
August 2024
Article Synopsis
- Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
- The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
- The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.
Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
Pediatr Allergy Immunol
May 2024
Article Synopsis
- The study investigates the impact of respiratory syncytial virus (RSV) on infants, highlighting that the effects go beyond just hospitalization and require better understanding for future healthcare planning.
- Researchers analyzed data from 6626 children, comparing those hospitalized with severe RSV to those who weren't, focusing on healthcare visits and prescriptions related to respiratory issues.
- Results showed that severe RSV significantly increased visits to primary healthcare for conditions like wheezing and lower respiratory infections, indicating a substantial burden even after initial hospitalization.
Background: Studies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5-11 and 12-17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.
Methods: A population-based test-negative control study was undertaken in Galicia, Spain.
Adverse events in pregnant women with the tetravalent influenza vaccine obtained from cell cultures.
Enferm Infecc Microbiol Clin (Engl Ed)
November 2022
Influenza vaccination in pregnant women shows a clear benefit/risk ratio. Influenza vaccines are currently being developed using new platforms. It is essential to analyse the safety of these new vaccines in this population group, underrepresented in clinical trials.
View Article and Find Full Text PDFBackground: Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vaccine effectiveness (VE) in comorbid patients are limited. We aimed to estimate booster dose VE against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients.
Method: A retrospective test-negative control study was undertaken in Galicia-Spain (December 2020-November 2021).
BACKGROUND: In response to increased case numbers of meningococcal group C disease, catch-up vaccination strategies have been shown to be successful. This paper describes the results of a repeat vaccination program in Galicia, Spain, and the strategy used for it. METHODS AND RESULTS: Three vaccination waves were performed: first, in 1996/1997 with a meningococcal group A and C polysaccharide vaccine in individuals aged 18 months to 19 years; second, in 2000 with a conjugate serogroup C polysaccharide vaccine in children born since 1993 and all children and adolescents up to 19 years not previously vaccinated; third, a campaign in 2006 that became necessary because of the development of a new Neisseria strain and an increase in both the incidence and lethality of meningococcal C disease.
View Article and Find Full Text PDF